扩大盆腔淋巴结清扫对接受根治性前列腺切除术的D'Amico中高危前列腺癌患者肿瘤学结局的影响:一项多中心研究
该多中心数据库纳入4个中心2000至2017年间9,742例接受根治性前列腺切除术的患者,仅纳入Briganti列线图淋巴结侵犯概率大于5%者。经2:1倾向性评分匹配后,盆腔淋巴结清扫组与未清扫组在120个月时的生化复发无生存率、无转移生存率和癌症特异性死亡无生存率均无显著差异(p分别为0.07、0.06、0.2)。
要点
- 共707例(7.3%)未行盆腔淋巴结清扫,其中520例为D'Amico中危、187例为高危。
- 清扫组中位淋巴结切除数为14枚(IQR 8-21),1,714例(19.0%)存在淋巴结转移。
- 倾向性评分匹配后,两组120个月肿瘤学结局均无显著差异(p分别为0.07、0.06、0.2)。
核心结论
- 在D'Amico中危或高危前列腺癌患者中,根治性前列腺切除术时行或不行盆腔淋巴结清扫的肿瘤学结局无显著差异。
- 盆腔淋巴结清扫的治疗价值仍不明确。
研究设计与样本
- 多中心数据库(4个中心)纳入2000至2017年间接受根治性前列腺切除术的9,742例患者,行或未行盆腔淋巴结清扫。
- 仅纳入Briganti列线图淋巴结侵犯概率大于5%的患者。
- 采用2:1倾向性评分匹配校正两组间潜在差异。
- 使用Cox回归模型检验盆腔淋巴结清扫对生化复发、转移和癌症特异性死亡的影响。
主要发现
- 总体707例(7.3%)未行盆腔淋巴结清扫,其中520例和187例分别具有D'Amico中危和高危特征。
- 清扫组中位切除淋巴结数为14枚(IQR 8-21),1,714例(19.0%)存在淋巴结转移。
- 倾向性评分匹配后,清扫组 vs 未清扫组在根治性前列腺切除术后120个月的生化复发无生存率为60.4% vs 65.6%(p=0.07),无转移生存率为87.0% vs 90.0%(p=0.06),癌症特异性死亡无生存率为95.2% vs 96.4%(p=0.2)。
- 校正术后和术前肿瘤特征的多因素Cox回归模型显示,根治性前列腺切除术时行盆腔淋巴结清扫并非生化复发、转移或癌症特异性死亡的独立预测因素(均p≥0.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pelvic lymph node dissection represents the gold standard of lymph node staging in patients with prostate cancer. We sought to assess the effect of extended pelvic lymph node dissection on oncologic outcomes in patients with characteristics of D'Amico intermediate or high risk prostate cancer treated with radical prostatectomy. MATERIALS AND METHODS: In a multi-institutional database of 4 centers we identified 9,742 patients who underwent radical prostatectomy from 2000 to 2017 with or without pelvic lymph node dissection. Only patients with a greater than 5% probability of lymph node invasion according to the Briganti nomogram were included in study. We performed 2:1 propensity score matching to account for potential differences between the 2 cohorts. Cox regression models were used to test the effect of pelvic lymph node dissection on biochemical recurrence, metastasis and cancer specific mortality. RESULTS: Overall 707 patients (7.3%) did not undergo pelvic lymph node dissection, of whom 520 and 187 harbored D'Amico intermediate and high risk characteristics, respectively. A median of 14 lymph nodes (IQR 8-21) were removed in the pelvic lymph node dissection cohort and 1,714 of these cases (19.0%) harbored lymph node metastasis. After propensity score matching the biochemical recurrence-free, metastasis-free and cancer specific mortality-free survival rates were 60.4% vs 65.6% (p=0.07), 87.0% vs 90.0% (p=0.06) and 95.2% vs 96.4% (p=0.2) for pelvic lymph node dissection vs no pelvic lymph node dissection 120 months after radical prostatectomy. Multivariable Cox regression models adjusted for postoperative and preoperative tumor characteristics revealed that pelvic lymph node dissection performed at radical prostatectomy was no independent predictor of biochemical recurrence, metastasis or cancer specific mortality (all p ≥0.1). CONCLUSIONS: There was no significant difference in oncologic outcomes in patients with D'Amico high or intermediate risk prostate cancer in whom pelvic lymph node dissection was or was not performed at radical prostatectomy. The therapeutic value of pelvic lymph node dissection remains unclear.
引用
- Preisser F, van den Bergh RCN, Gandaglia G, et al. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. J Urol. 2019. PMID: 31437119. doi:10.1097/JU.0000000000000504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。